Log in

OTCMKTS:MRNAMarina Biotech Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$58.19
-2.40 (-3.96 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$56.63
Now: $58.19
$59.19
50-Day Range
$12.17
MA: $14.00
$15.31
52-Week Range
$11.54
Now: $58.19
$29.79
Volume14.65 million shs
Average Volume1.15 million shs
Market Capitalization$19.15 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Marina Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of proprietary drug therapeutics primarily for hypertension, arthritis, pain, and oncology in the United States, Europe, and internationally. The company offers Prestalia, a single-pill fixed dose combination (FDC) of perindopril argenine, an angiotensin-converting-enzyme inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension. Its clinical development programs include IT-102 and IT-103, a celecoxib program drug candidates for the treatment of combined arthritis pain/hypertension and the treatment of pain requiring a high dose of celecoxib; CEQ508, an oral delivery of small interfering RNA against beta-catenin, combined with IT-102 to suppress polyps in the precancerous syndrome and orphan indication familial adenomatous polyposis; and CEQ508 combined with IT-103 to treat colorectal cancer. The company is headquartered in City of Industry, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.73 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MRNA
Previous SymbolOTCMKTS:MRNAD
CUSIPN/A
Phone626-964-5788

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$19.15 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive MRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter.

Marina Biotech (OTCMKTS:MRNA) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Marina Biotech?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marina Biotech in the last year. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Marina Biotech.

How were Marina Biotech's earnings last quarter?

Marina Biotech, Inc. (OTCMKTS:MRNA) announced its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.01. The biotechnology company earned $4.46 million during the quarter, compared to analyst estimates of $17.60 million. Marina Biotech's quarterly revenue was down 72.1% on a year-over-year basis. View Marina Biotech's earnings history.

What price target have analysts set for MRNA?

12 equities research analysts have issued 12 month target prices for Marina Biotech's shares. Their forecasts range from $20.00 to $112.00. On average, they anticipate Marina Biotech's stock price to reach $77.50 in the next year. This suggests a possible upside of 33.2% from the stock's current price. View analysts' price targets for Marina Biotech.

Has Marina Biotech been receiving favorable news coverage?

Headlines about MRNA stock have trended negative this week, InfoTrie reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Marina Biotech earned a news impact score of -2.8 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the near term. View the latest news aboutMarina Biotech.

Who are some of Marina Biotech's key competitors?

What other stocks do shareholders of Marina Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marina Biotech investors own include Gilead Sciences (GILD), Micron Technology (MU), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Pfizer (PFE), Bank of America (BAC), Alibaba Group (BABA), Walt Disney (DIS) and Intel (INTC).

Who are Marina Biotech's key executives?

Marina Biotech's management team includes the following people:
  • Mr. Erik Emerson, Chief Commercial Officer & Director (Age 47)
  • Mr. Robert C. Moscato Jr., CEO & Director (Age 42)
  • Mr. Amit Shah, Chief Financial Officer (Age 52)
  • Mr. Mihir Munsif, Chief Operating Officer (Age 55)
  • Dr. Larn Hwang, Chief Scientific Officer (Age 55)

What is Marina Biotech's stock symbol?

Marina Biotech trades on the OTCMKTS under the ticker symbol "MRNA."

Who are Marina Biotech's major shareholders?

Marina Biotech's stock is owned by many different retail and institutional investors. Top institutional shareholders include Moloney Securities Asset Management LLC (0.01%), Nvwm LLC (0.01%), Comerica Bank (0.00%), Bainco International Investors (0.00%), Arkadios Wealth Advisors (0.00%) and Verus Capital Partners LLC (0.00%). Company insiders that own Marina Biotech stock include Lorence H Kim, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks and Ventures Fund Iv Gene Flagship. View institutional ownership trends for Marina Biotech.

Which institutional investors are selling Marina Biotech stock?

MRNA stock was sold by a variety of institutional investors in the last quarter, including Sowell Financial Services LLC, and Moloney Securities Asset Management LLC. Company insiders that have sold Marina Biotech company stock in the last year include Lorence H Kim, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks, and Ventures Fund Iv Gene Flagship. View insider buying and selling activity for Marina Biotech.

Which institutional investors are buying Marina Biotech stock?

MRNA stock was bought by a variety of institutional investors in the last quarter, including Nvwm LLC, Comerica Bank, Bainco International Investors, Arkadios Wealth Advisors, Verus Capital Partners LLC, Valeo Financial Advisors LLC, EPG Wealth Management LLC, and Patriot Financial Group Insurance Agency LLC. View insider buying and selling activity for Marina Biotech.

What is Marina Biotech's stock price today?

One share of MRNA stock can currently be purchased for approximately $58.19.

How big of a company is Marina Biotech?

Marina Biotech has a market capitalization of $19.15 billion.

What is Marina Biotech's official website?

The official website for Marina Biotech is www.marinabio.com.

How can I contact Marina Biotech?

Marina Biotech's mailing address is 17870 CASTLETON STREET SUITE 250, CITY OF INDUSTRY CA, 91748. The biotechnology company can be reached via phone at 626-964-5788 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.